Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction

• Status: Recruiting
• Trial end date: 2024-12-15
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the relationship between NT-proBNP and empagliflozin effects in patients with chronic heart failure with mildly reduced ejection fraction (HFmrEF 41-49%) and reduced ejection fraction (HFrEF ≤40%) whether diabetic or non-diabetic patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Treatments: Empagliflozin

Criteria

Inclusion Criteria:

• Chronic heart failure with mildly reduced ejection fraction (41-49%) and reduced ejection fraction (≤40%)

• 18-70 years

• Not receiving empagliflozin or any SGLT2 inhibitor

• Elevated plasma NT-proBNP (≥125 pg/ml)

• eGFR ≥ 20 ml/min/1.73m2

Exclusion Criteria:

• Acute Coronary Syndrome (ACS)

• Pulmonary embolism

• Myocarditis

• Valvular heart disease

• Hypertrophic or restrictive cardiomyopathy

• Congenital heart disease

• Pulmonary hypertension

• Surgical procedures involving the heart

• Heart contusion

• Cardioversion, Implantable Cardioverter Defibrillator (ICD) shock

• Patients receiving digoxin

• Advanced age (>70years)

• Ischemic stroke

• Chronic Obstructive Pulmonary Disease

• Subarachnoid haemorrhage

• Severe infection (including pneumonia and sepsis)

• Anemia

• Renal dysfunction (eGFR <20ml/min/1.73m2)

• Liver dysfunction (mainly liver cirrhosis with ascites- Child Pugh B & C)

• Severe burns

• Paraneoplastic syndrome

• Severe metabolic and hormone abnormalities (e.g thyrotoxicosis, diabetic ketosis)